Baricitinib for Graft-Versus-Host Disease Prophylaxis after HLA-matched Hematopoietic Cell Transplantation
Abstract Acute graft-versus-host disease (aGVHD) is a leading cause of non-relapse mortality after allogeneic peripheral blood hematopoietic cell transplant (PB-HCT). The role of baricitinib, a balanced JAK1/2 inhibitor, for GvHD prophylaxis is unknown. Baricitinib after HLA-matched allogeneic PB-HCT was studied in a single-arm, open-label, phase I trial in 24 subjects. Subjects received baricitinib at 2 or 4 mg daily from days − 3 to + 100 post PB-HCT, followed by a taper. No primary graft failure, delayed engraftment or grade III/IV adverse events were observed. Overall incidence of grade III/IV aGVHD was 12.5% (3/24), of which 2/3 occurred after baricitinib discontinuation. Mild-moderate chronic GVHD occurred in 45.8% subjects, with no cases of severe chronic GVHD. Transplant-related mortality at day + 180 was 8% (2/24). The 1-year OS was 70% (95% CI 48–85%), PFS 62% (95% CI 40–78%), and refined GVHD and relapse free survival (GRFS) 33% (95% CI 15–52%). Correlative studies confirmed on-target effect of baricitinib resulting in downregulation of JAK1/2 pathways. Baricitinib is safe and tolerable after HLA-matched allogeneic PB-HCT with no episodes of primary graft failure and low rates of grade III/IV acute GVHD while on therapy.
Authors
- Zachary David Crees (ORCID: https://orcid.org/0000-0003-3215-8454)
- Amanda F. Cashen (ORCID: https://orcid.org/0000-0001-6809-4566)
- Ramzi Abboud (ORCID: https://orcid.org/0000-0001-7786-4155)
- Jeffery King
- Iskra Pusic (ORCID: https://orcid.org/0000-0003-1725-5184)
- Jaebok Choi (ORCID: https://orcid.org/0000-0002-5590-087X)
- Melinda Harding
- Jeremy Eisele
- John F. DiPersio (ORCID: https://orcid.org/0000-0002-0429-3133)
- Sena Kim (ORCID: https://orcid.org/0000-0002-6930-2416)
- Arun Čumpelik
- Armin Ghobadi (ORCID: https://orcid.org/0000-0001-8848-8474)
- Mark A. Schroeder (ORCID: https://orcid.org/0000-0003-4924-8990)
- Geoffrey L. Uy (ORCID: https://orcid.org/0000-0002-7809-0996)
- Feng Gao (ORCID: https://orcid.org/0009-0007-8910-4760)
- Camille N. Abboud (ORCID: https://orcid.org/0000-0002-5469-8534)
- Peter Westervelt
- Meagan A. Jacoby
- Sora Lim
Institutions
- Washington University in St. Louis (US)
- MaineHealth (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11066216/v1
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- preprint
Funders
- Foundation for Barnes-Jewish Hospital
- Institute of Clinical and Translational Sciences
- Gabrielle's Angel Foundation for Cancer Research
- Alvin J. Siteman Cancer Center
- Swim Across America
- Incyte
- Syndax Pharmaceuticals
- Novo Nordisk
- National Institutes of Health
- National Cancer Institute
- National Center for Advancing Translational Sciences